Intellia Therapeutics Inc (NTLA)
14.50
-0.16
(-1.06%)
USD |
NASDAQ |
Dec 04, 16:00
14.49
0.00 (0.00%)
After-Hours: 20:00
Intellia Therapeutics Revenue (Quarterly): 9.111M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 9.111M |
| June 30, 2024 | 6.957M |
| March 31, 2024 | 28.94M |
| December 31, 2023 | -1.917M |
| September 30, 2023 | 11.99M |
| June 30, 2023 | 13.59M |
| March 31, 2023 | 12.61M |
| December 31, 2022 | 13.57M |
| September 30, 2022 | 13.27M |
| June 30, 2022 | 14.03M |
| March 31, 2022 | 11.25M |
| December 31, 2021 | 12.85M |
| September 30, 2021 | 7.204M |
| June 30, 2021 | 6.55M |
| March 31, 2021 | 6.445M |
| December 31, 2020 | 6.595M |
| September 30, 2020 | 22.22M |
| June 30, 2020 | 16.26M |
| March 31, 2020 | 12.92M |
| December 31, 2019 | 10.94M |
| Date | Value |
|---|---|
| September 30, 2019 | 10.62M |
| June 30, 2019 | 11.12M |
| March 31, 2019 | 10.43M |
| December 31, 2018 | 7.88M |
| September 30, 2018 | 7.408M |
| June 30, 2018 | 7.677M |
| March 31, 2018 | 7.469M |
| December 31, 2017 | 6.668M |
| September 30, 2017 | 7.317M |
| June 30, 2017 | 5.917M |
| March 31, 2017 | 6.215M |
| December 31, 2016 | 5.627M |
| September 30, 2016 | 4.869M |
| June 30, 2016 | 4.206M |
| March 31, 2016 | 1.777M |
| December 31, 2015 | 1.693M |
| September 30, 2015 | 1.688M |
| June 30, 2015 | 1.377M |
| March 31, 2015 | 1.286M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-1.917M
Minimum
Dec 2023
28.94M
Maximum
Mar 2024
11.77M
Average
12.30M
Median
Revenue (Quarterly) Benchmarks
| BridgeBio Pharma Inc | 2.732M |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Ionis Pharmaceuticals Inc | 133.81M |
| Pfizer Inc | 17.70B |
| Regeneron Pharmaceuticals Inc | 3.721B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -135.71M |
| Total Expenses (Quarterly) | 153.88M |
| EPS Diluted (Quarterly) | -1.34 |
| Enterprise Value | 833.97M |
| Profit Margin (Quarterly) | -1.49K% |
| Earnings Yield | -37.53% |
| Normalized Earnings Yield | -35.43 |